Innocan Pharma Corporation announces the filing of an international patent application for Topical Composition for the Treatment of Diabetic Symptoms. The patent application discloses and makes claims for several compositions for topical administration comprising of cannabinoid for the treatment of diabetic related conditions. Specifically, the compositions enable enhancing of blood flow to peripheral areas in patients suffering from diabetes symptoms. Innocan is expanding its intellectual property portfolio of cannabis-based products to be a source of potential breakthroughs in skin therapy as well as for further opportunities across the broad spectrum of inflammatory indications with currently unmet medical needs.